Inhaled aerosol viral-vectored vaccines against tuberculosis.
Curr Opin Virol
; 66: 101408, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38574628
ABSTRACT
Bacille Calmette-Guérin (BCG) remains the sole licensed vaccine against tuberculosis (TB), despite its variable efficacy in protecting against pulmonary TB. The development of effective TB vaccines faces significant challenges, marked by the absence of validated correlates of protection and predictive animal models. Strategic approaches to enhance TB vaccines and augment BCG efficacy include utilising prime-boost strategies with viral-vectored vaccines and exploring innovative delivery techniques, such as mucosal vaccine administration. Viral vectors offer numerous advantages, including the capacity to accommodate genes encoding extensive antigenic fragments and the induction of robust immune responses. Aerosol delivery aligns with the route of Mycobacterium tuberculosis infection and holds the potential to enhance protective mucosal immunity. Aerosolised viral-vectored vaccines overcome anti-vector immunity, facilitating repeated aerosol deliveries.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tuberculose
/
Aerossóis
/
Vacinas contra a Tuberculose
/
Vetores Genéticos
/
Mycobacterium tuberculosis
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Virol
Ano de publicação:
2024
Tipo de documento:
Article